Concerns regarding stem cell mobilization in liposomal mitoxantrone therapy for relapsed/refractory T‐cell/natural killer‐cell lymphomas

Documenti analoghi

• Efficacy and side effects of anti‐CD19 CAR T‐cell therapy in patients with relapsed/refractory gastrointestinal lymphoma
  di: Yi Li Jiang, et al.
  Pubblicazione: (2024)
• Outcomes of pirtobrutinib for relapsed/refractory mantle cell lymphoma in compassionate use program in Europe
  di: Enver Aydilek, et al.
  Pubblicazione: (2024)
• Combination of mitoxantrone hydrochloride liposome with cyclophosphamide, vincristine, and prednisone for patients with treatment‐naive peripheral T‐cell lymphoma: A multicenter, open‐label, single‐arm, phase 1b trial
  di: Yan Gao, et al.
  Pubblicazione: (2026)
• Second‐line chimeric antigen receptor T‐cell therapy versus standard of care in relapsed or refractory large B‐cell lymphoma: A systematic review and meta‐analysis
  di: Lingrong Tang, et al.
  Pubblicazione: (2026)
• Infections associated with CAR ‐T cell therapy in patients with relapsed refractory multiple myeloma: Risks and prevention strategies
  di: Jing An, et al.
  Pubblicazione: (2024)